PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31652041-0	2019	Mid-dose losartan mitigates diabetes-induced hepatic damage by regulating iNOS, eNOS, VEGF, and NF-kappaB expressions Background/aim: Losartan,  an  antihypertensive  drug,  is  highly  preferred  in  patients  with  diabetes  mellitus  (DM)  and  hypertension  because of its retarding effect on diabetic nephropathy.	Losartan	9-17	nitric oxide synthase 3	Homo sapiens	80-84	
31652041-0	2019	Mid-dose losartan mitigates diabetes-induced hepatic damage by regulating iNOS, eNOS, VEGF, and NF-kappaB expressions Background/aim: Losartan,  an  antihypertensive  drug,  is  highly  preferred  in  patients  with  diabetes  mellitus  (DM)  and  hypertension  because of its retarding effect on diabetic nephropathy.	Losartan	134-142	nitric oxide synthase 3	Homo sapiens	80-84	
31652041-6	2019	Conclusion: This  study  indicated  that  mid-dose  losartan  administration  may  have  a  therapeutic  effect  by  inhibiting  apoptosis  and  regulating iNOS, eNOS, VEGF, and NF-kappaB protein expressions in DM-induced hepatic damage.	Losartan	52-60	nitric oxide synthase 3	Homo sapiens	162-166